MZB1 and ovarian carcinoma: Figure 2b shows the sites of MZB1 genetic alterations, including the R163L/Q alteration (Figure 2c). However, ovarian cancer cases with MZB1 alterations showed no OS advantage compared to those without alterations (log rank p = 0.964, Figure S1c).